These data strongly suggest that the activation of both MAPK and PI3K/AKT pathways are a frequent event in melanoma radioresistance, and combining PRIMA-1Met with Vemurafenib acts synergistically with RT to trigger melanoma growth inhibition by affecting these two important signaling pathways. This evidence concerns the gene AKT1 and melanoma.